StreetInsider.com News Articles

Form 4 CODEXIS, INC. For: Oct 12 Filed by: Erbez Georgia

Wed, 14 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261014/27187928.html

Form 4 CODEXIS, INC. For: Oct 12 Filed by: MOORE ALISON

Wed, 14 Oct 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20261014/27187911.html

Form 144 CODEXIS, INC. Filed by: Erbez Georgia

Tue, 13 Oct 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20261013/27181583.html

Form 144 CODEXIS, INC. Filed by: MOORE ALISON

Tue, 13 Oct 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20261013/27181477.html

Codexis signs siRNA deal to test its ECO Synthesis platform

Mon, 28 Sep 2026 06:01:56 -0400

Codexis, Inc. (NASDAQ: CDXS) announced an agreement with an undisclosed siRNA drug developer to explore stereo-defined oligonucleotide fragment synthesis using its ECO Synthesis Manufacturing Platform, according to a company press release dated Sept. 28, 2026.

Under the agreement, Codexis will produce stereo-defined oligonucleotide fragments through a fully enzymatic process. Those fragments will then be supplied to the partner company to assemble into a final duplex via ligation. The collaboration will also compare the enzymatically synthesized fragments against conventional solid-phase oligonucleotide synthesis (SPOS), evaluating purity, product quality, and ligation performance.

The agreement follows a presentation at TIDES USA 2026, where Codexis said it

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Mon, 28 Sep 2026 06:00:00 -0400

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.

The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis.

Under the agreement, Codexis will use its ECO Synthesis

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Mon, 28 Sep 2026 06:00:00 -0400

Under the agreement, Codexis will use its ECO Synthesis

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.

Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay will be archived for 90 days following the

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

Benchmark Reiterates Hold Rating on Codexis, Inc. (CDXS) Amid Transition to New Products/Services

Thu, 20 Aug 2026 09:18:14 -0400

Benchmark analyst Robert Wasserman reiterated a Hold rating and {REMOVEPT} price target on Codexis, Inc. (NASDAQ: CDXS).

The analyst commented, "Codexis reported in-line financial results for their 2Q26, including revenues of $14.9 million, down 3% year-overyear, with a reduced net loss of $12.0 million or ($0.13) per share as compared to $13.2 million or ($0.16) per share in 2Q26. Revenues were led in 2Q26 by $13.2 million from product sales, up from $7.4 million the prior year, offset by reduced R&D revenues of $1.7 million versus $7.9 million last year. Our estimates had been revenues of $14.5 million and a net

Codexis, Inc. (CDXS) PT Lowered to $8 at Piper Sandler

Mon, 17 Aug 2026 07:43:33 -0400

Piper Sandler analyst Do Kim lowered the price target on Codexis, Inc. (NASDAQ: CDXS) to $8.00 (from $9.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26919789.html

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26919789.html

Codexis (CDXS) Tops Q2 EPS by 1c

Tue, 11 Aug 2026 16:42:11 -0400

Codexis (NASDAQ: CDXS) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.92 million versus the consensus estimate of $13.82 million.

For earnings history and earnings-related data on Codexis (CDXS) click here.

Form 10-Q CODEXIS, INC. For: Jun 30

Tue, 11 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26906125.html

Form 10-Q CODEXIS, INC. For: Jun 30

Tue, 11 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26906125.html

Form 8-K CODEXIS, INC. For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905813.html

Form 8-K CODEXIS, INC. For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905813.html

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

Codexis adds David Butler to its strategic advisory board

Mon, 03 Aug 2026 09:00:26 -0400

Codexis, Inc. (Nasdaq: CDXS) has appointed David Butler, PhD, to its Strategic Advisory Board, the company announced. Concurrently, Carole Cobb is stepping down from the board.

Butler brings more than 20 years of experience in the oligonucleotide field. He most recently served as Chief Technology Officer at Hongene Biotech Corporation from 2023 to 2026. Before that, he held chemistry leadership roles at Wave Life Sciences, Korro Bio, and Alltrna. Earlier in his career at Alnylam, he contributed to the development of liquid nanoparticle delivery technologies. He holds a BSc and PhD in Chemistry from St. Andrews University.

Alison Moore, PhD, President and